Patent 11787860 was granted and assigned to Celgene on October, 2023 by the United States Patent and Trademark Office.
Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.